Durvalumab — Dosing in CKD & Dialysis
Durvalumab (Immunotherapy): renal dosing adjustments, dialyzability (Not studied in the label (no statement on removal by dialysis); human IgG1 kappa monoclonal antibody (Imfinzi label 11). Level estimated from molecule size or protein binding; not measured.), and renal-relevant safety risk for CKD
Reviewed by Matt · November 16, 2026